Fintel reports that on March 21, 2025, Goldman Sachs initiated coverage of Sanofi - Depositary Receipt () (NasdaqGS:SNY) with a Neutral recommendation. As of March 19, 2025, the average one-year ...

Below is Validea's guru fundamental report for SANOFI SA (ADR) (SNY). Of the 22 guru strategies we follow, SNY rates highest using our Acquirer's Multiple Investor model based on the published ...

The Goldman Sachs Group started coverage on shares of Sanofi (NASDAQ:SNY – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The firm issued a neutral ...

Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

Sanofi develops therapeutic products for diabetes ... Here are a few to get you started, listed in alphabetical order. CoCrystal Pharma (NASDAQ:COCP) CoCrystal Pharma is a clinical-stage biotech ...

FDA’s Priority Tag to SNY’s Dupixent sBLA for Bullous Pemphigoid Sanofi and Regeneron announced that the FDA has accepted and granted priority review to an sBLA seeking approval of Dupixent ...

Saint Gobain, Sanofi and L'Oreal are up 1 to 1.2% ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Renault, Air Liquide, Accor, Essilor, Pernod Ricard, Sanofi and Vivendi are advancing ... the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the ...

Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review to the regulatory submission of tolebrutinib ...

Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bios autoimmune disease treatment, DR-0201, reinforcing its ...